Broadcast Date: June 9th, 2016
Time: 11:00 am ET, 8:00 am PT
Learn how advances in human induced pluripotent stem cell (iPSC) technology enable early detection and avoidance of neuro-, cardio-, and hepatotoxicity during drug development. The Cellular Dynamics line of iCell® products are fully differentiated human cells derived from iPSCs. iCell GlutaNeurons are a population of excitatory neurons that bring previously inaccessible human biology to the lab bench for both discovery and toxicity (seizurogenic) investigations. iCell Hepatocytes 2.0 maintain appropriate function longer than existing models and over extended culture periods, thus providing a relevant means for acute and sub-chronic toxicity testing in human tissue cells. iCell Cardiomyocytes exhibit electrical and contractile behavior that is translatable to both the human condition and more costly animal models. This webinar will provide examples from industry experts on how iPSC technology can have a meaningful impact on your day to day research.
Who Should Attend:
- Discovery and investigative toxicologists
- Safety pharmacologists
- Translational scientists
- Anyone interested in learning about the impact of iPSC technology on drug discovery and toxicity testing
You Will Learn:
- A greater understanding of the advantages and limitations of iPSC-derived neurons, cardiomyocytes, and hepatocytes as tools for early and robust toxicity detection.
- Procedures for implementing iPSC-derived cell types in your lab.
- Most importantly, examples of how iPSC-derived cell types can accelerate your research.
Produced with support from:
Panelists
Brad Swanson, Ph.D.
Vice President, R&D: Cell Biology,
Cellular Dynamics International, a FUJIFILM company
Andrew Bruening-Wright, Ph.D.
Principal Scientist,
Charles River Laboratories
William Proctor, Ph.D., DABT
Scientist, Investigative Toxicology,
Genentech
